Atlas Trials

Open-label, Bioequivalence Study of Certolizumab Pegol 200 mg Solution Injected Either by a Prefilled Syringe (Reference) or by an E-Device (Test) in Healthy Subjects

Clinical trial NCT02806219 · COMPLETED

Trial details

NCT number
NCT02806219
Sponsor
UCB BIOSCIENCES, Inc.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Healthy
Start date
2016-03-01
Primary completion
2016-11-01
Enrollment
100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.